DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for immunodeficiency, common variable, 3 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleImmunodeficiency, common variable, 3 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for immunodeficiency, common variable, 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
CD19 molecule (CD19) — CD19 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7JIC · 3.8 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
The 2009 update on common variable immunodeficiency disorders describes them as a mixed group of heterogeneous conditions linked by lack of immunoglobulin production and primary antibody failure. The authors note that this variability makes it difficult to make coherent sense of immunopathogenesis or the role of various genetic abnormalities reported in the literature. They report that a recent attempt to collate the varied complications and define particular clinical phenotypes has improved understanding, but state that these definitions need to be refined and confirmed by other studies before they can facilitate improved accuracy of prognosis or better management of clinical complications.
A 2005 prospective cohort study evaluated an HIV postexposure prophylaxis protocol in 347 rape victims seen from May 1997 to October 2001. PEP was offered to 278 victims, with 141 in a moderate-exposure group receiving Zdv plus 3TC and 137 in a high-exposure group receiving Zdv plus 3TC plus a protease inhibitor. Side effects were more common in the triple-therapy group (P < 0.01). No seroconversion was diagnosed in the 180 victims who completed six months of follow-up. The authors concluded that triple therapy was associated with side effects and that drug regimes should be reviewed.
A 2021 case report presents radiological findings in a single 20-year-old patient with laboratory findings supporting a diagnosis of common variable immunodeficiency. The authors state that radiological findings and clinical suspicion could be helpful in diagnosing the condition, thereby decreasing mortality and morbidity.
A 2013 textbook chapter on primary immunodeficiency lists common variable immunodeficiency under major B-lymphocyte disorders and notes that it has complications and treatment, but provides no specific data on outcomes, response rates, or survival from any trial.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Haematology · 2009 · 392 citations · open access
Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions
AbstractThe common variable immunodeficiency disorders are a mixed group of heterogeneous conditions linked by lack of immunoglobulin production and primary antibody failure. This variability results in difficulty in making coherent sense of either immunopathogenesis or the role of various genetic abnormalities reported in the literature. The recent attempt to collate the varied complications in these conditions and to define particular clinical phenotypes has improved our understanding of these diseases. Once refined and confirmed by other studies, these definitions will facilitate improved accuracy of prognosis and better management of clinical complication. They may also provide a method of analysing outcomes as related to new immunopathological and genetic findings.
Postexposure Prophylaxis After Sexual Assaults: A Prospective Cohort Study
AbstractOBJECTIVE: The objective of this study was to evaluate HIV postexposure prophylaxis (PEP) protocol in rape victims. STUDY: The victims were assigned to 1 of 3 categories, according to the severity of exposure (I-low, II-moderate, III-high). HIV PEP was provided to victims in groups II (Zdv + 3TC) and III (Zdv + 3TC + PI) until 72 hours after exposure. The follow-up was 6 months. RESULTS: From May 1997 to October 2001, 347 victims were attended. PEP was offered to 278 victims (141 in group II and 137 in group III). Side effects were more common in group III (P <0.01). No seroconversion was diagnosed in the 180 victims that completed the follow-up. Univariate analysis showed that the schooling level, knowledge of the aggressor's HIV status, and the use of PEP were associated with compliance. CONCLUSIONS: Triple therapy was associated with side effects, which suggested that drug regimes should be reviewed. The variables related to a high risk of HIV transmission were also significant for compliance.
Indian Journal of Allergy Asthma and Immunology · 2021 · 0 citations · open access
Imaging findings in common variable immunodeficiency
AbstractCommon variable immunodeficiency is characterized by decreased levels of immunoglobulins leading to repeated infections of chest, gastrointestinal tract, etc., Radiological findings and clinical suspicion could be helpful in diagnosing common variable immunodeficiency thereby decreasing mortality and morbidity associated with disease. We present radiological findings in a 20-year-old patient with laboratory findings supporting the diagnosis of common variable immunodeficiency.
Oxford University Press eBooks · 2013 · 0 citations
Primary immunodeficiency
AbstractIntroduction Classification of immunodeficiency Clinical features of immunodeficiency Investigation of immunodeficiency Laboratory investigation Major B-lymphocyte disorders Rare antibody deficiency syndromes X-linked agammaglobulinaemia (Bruton’s disease) Common variable immunodeficiency (CVID) CVID 2: complications and treatment Selective IgA deficiency IgG subclass deficiency Specific antibody deficiency with normal serum immunoglobulins...
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
